Showing 4461-4470 of 9718 results for "".
- Alastin SkinCare Appoints Lynn Salo to Board of Directorshttps://practicaldermatology.com/news/alastin-skincare-appoints-linda-salo-to-board-of-directors/2458719/Lynn Salo is now a member of ALASTIN™ Skincare, Inc.’s board of directors. Ms. Salo has 27 years of experience with Allergan in the U.S., Canada, and Europe, including her role as Vice President, Sales and Marketing for the Facial Aesthetic
- Survey: When it Come to Facial Aging Concerns, It's Like Mother, Like Daughterhttps://practicaldermatology.com/news/survey-when-it-come-to-facial-aging-concerns-its-like-mother-like-daughter/2458720/Galderma’s latest campaign Mom Genes™ aims to change the way moms and daughters talk about and approach facial aging. Fully 82 percent of moms hope facial aging is easier for their daughters, but more than half never talk about it togethe
- Bristol-Myers Squibb's Opdivo + Yervoy Regimen Receives Expanded FDA Approval in Unresectable or Metastatic Melanoma Across BRAF Statushttps://practicaldermatology.com/news/bristol-myers-squibbs-opdivo-yervoy-regimen-receives-expanded-fda-approval-in-unresectable-or-metastatic-melanoma-across-braf-status/2458732/The FDA has approved Bristol-Myers Squibb’s Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the treatment of patients with BRAF V600 wild-type and BRAF V600 mutation-positive unresectable or metastatic melanoma. This indication is
- Psoria-Shield, Inc. Names Dr. Steven Feldman as Scientific Advisorhttps://practicaldermatology.com/news/psoria-shield-inc-names-dr-steven-feldman-as-scientific-advisor/2458754/Psoria-Shield, Inc. Names Dr. Steven Feldman as Scientific Advisor Wellness Center USA, Inc.’s wholly owned subsidiary, Psoria-Shield, Inc. (PSI) named Steven Feldman, MD, PhD as Scientific Advisor. Dr. Feldman is a Professor of Dermatology, Professor of Pathology, and Professor of
- Oculus Innovative Sciences Receives FDA Clearance for Microcyn-Based SebDerm Gelhttps://practicaldermatology.com/news/oculus-innovative-sciences-receives-fda-clearance-for-microcyn-based-sebderm-gel/2458780/Oculus Innovative Sciences, Inc. received a new 510(k) clearance from the FDA for the company’s new Microcyn®-based SebDerm Gel. As a prescription product, SebDerm Gel is intended to manage and relieve the burning, itching, erythema, scaling, and pain experienced with seborrh
- Syneron Appoints Jeff Nardoci as President of North America Body Shaping Grouphttps://practicaldermatology.com/news/syneron-appoints-jeff-nardoci-as-president-of-north-america-body-shaping-group/2458820/Syneron Medical Ltd., a leading global aesthetic device company, appointed Jeff Nardoci as President of its North America Body Shaping Group. In this position, Mr. Nardoci will be responsible for the development and execution of the company's growth strategies for UltraShape and VelaShape. He
- Syneron Candela Announces New FDA Clearance for the CO2RE Systemhttps://practicaldermatology.com/news/syneron-candela-announces-new-fda-clearance-for-the-co2re-system/2458825/The FDA has granted numerous additional indications for use of Syneron Medical Ltd.’s CO2RE CO2 device. This clearance, including more than 90 specific indications in total, significantly expands the business opportunity for CO2RE users for high patient dema
- New Tattoo Survey Shows Tattoo Acceptance Up; Tattoo Regret Still an Issuehttps://practicaldermatology.com/news/new-tattoo-survey-shows-tattoo-acceptance-up-tattoo-regret-still-an-issue/2458826/With nearly 40 percent of Americans ages 18-29 sporting ink, body art has not only become mainstream, but can actually up someone's stock. In a recent Syneron Candela survey, attitudes toward people with tattoos were overwhelmingly positive, being described as artistic and creative (50 percen
- FDA Approves Yervoy for Adjuvant Treatment for Fully Resected Stage III Melanomahttps://practicaldermatology.com/news/fda-approves-yervoy-for-adjuvant-treatment-for-fully-resected-stage-iii-melanoma/2458829/The FDA approved Bristol-Myers Squibb Company’s Yervoy (ipilimumab) 10 mg/kg for the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1mm who have undergone complete resection including total lymphadenectomy. Th
- Phase 3 Data Show Promius Pharma's DFD-01 Met Primary Endpoints for the Treatment of Moderate Psoriasishttps://practicaldermatology.com/news/phase-3-data-show-promius-pharmas-dfd-01-met-primary-endpoints-for-the-treatment-of-moderate-psoriasis/2458833/Findings from two Phase III studies for Promius Pharma’s investigational psoriasis drug DFD-01 show that the agent achieved the primary endpoint at day 15. The primary endpoint was the proportion of patients achieving treatment success at day 15 for both studies. In addition, both stud